Medical Devices

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

NeuroPace will present its RNS System at the Leerink conference, a key moment for the company to showcase its epilepsy treatment to top investors.

As Hyperfine preps its 2025 results, investors and clinicians watch to see if its portable Swoop MRI can translate clinical promise into financial success.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

VIO Med Spa is using an advanced training university to standardize excellence, drive rapid franchise growth, and define the future of aesthetic medicine.

With a new SVP of Global Sales, Slingshot Biosciences is poised to scale its synthetic cell mimic technology, targeting the booming cell therapy market.

Sarah Sommer, a deaf digital marketing exec, joins the Oberkotter Foundation board, blending personal insight with corporate strategy to advance hearing healthcare.

With data from 150M patients, SEQSTER's new platform promises to accelerate drug development, improve trial diversity, and make research-ready data a reality.

As burnout plagues radiology, Fujifilm unveils AI workflow solutions at HIMSS 2026 aimed at easing workloads and boosting hospital efficiency.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

Investors watch closely as CytoSorbents balances a push for profitability with high-stakes regulatory hurdles for its life-saving blood purification tech.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

A novel oral drug for Alzheimer's avoids a key side effect of current therapies, as its 'detangler' platform shows promise for Parkinson's and other diseases.

A new global survey reveals the crushing mental burden of diabetes, sparking a call for AI-powered tools that promise to restore spontaneity and control.

Phonak's new hearing aids won a top design award, blending advanced AI with discreet style to change how we see and hear with assistive technology.

The Japanese giant is turning period poverty and gender disparity into a business model, using pads and education to unlock new markets in China, Brazil, and Kenya.